



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/567,876	02/08/2006	Yohannes Tesfaigzi	41543-0302-US	2360

5179 7590 12/02/2008
PEACOCK MYERS, P.C.
201 THIRD STREET, N.W.
SUITE 1340
ALBUQUERQUE, NM 87102

EXAMINER

GOLDBERG, JEANINE ANNE

ART UNIT	PAPER NUMBER
----------	--------------

1634

MAIL DATE	DELIVERY MODE
-----------	---------------

12/02/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/567,876	Applicant(s) TESFAIGZI ET AL.	
	Examiner JEANINE A. GOLDBERG	Art Unit 1634	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 8/30/08.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-19 is/are pending in the application.
- 4a) Of the above claim(s) 10-19 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-9 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 2/28/06 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. This action is in response to the papers filed August 30, 2008. Currently, claims 1-19 are pending. Claims 10-19 have been withdrawn as drawn to non-elected subject matter.
2. All arguments have been thoroughly reviewed but are deemed non-persuasive for the reasons which follow. This action is made FINAL.
3. Any objections and rejections not reiterated below are hereby withdrawn.

Election/Restrictions

4. Applicant's election without traverse of Group I, Claims 2-9 in the paper filed April 28, 2008 is acknowledged.

The applicant correctly acknowledges that 10-19 are withdrawn. Generic Claim 1 will be examined with Group I. In the event Claim 1 becomes allowable, the linked inventions will be considered.

The requirement is still deemed proper and is therefore made FINAL.

Priority

5. This application is a 371 of PCT/US04/26035, filed August 11, 2004 and claims benefit of 60/494,631, filed August 11, 2003.

Drawings

6. The drawings are acceptable.

Maintained Rejections

Claim Rejections - 35 USC § 112- Enablement

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claims 1-9 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Factors to be considered in determining whether a disclosure meets the enablement requirement of 35 USC 112, first paragraph, have been described by the court in *In re Wands*, 8 USPQ2d 1400 (CA FC 1988). *Wands* states at page 1404,

“Factors to be considered in determining whether a disclosure would require undue experimentation have been summarized by the board in *Ex parte Forman*. They include (1) the quantity of experimentation necessary, (2) the amount of

Art Unit: 1634

direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims.”

The nature of the invention and breadth of claims

The claims are drawn to a method for determining susceptibility of a Hispanic and non-Hispanic white men to a COPD excluding asthma and chronic bronchitis, comprising determining the presence of an exon 6 codon 279 SNP within MMP-9 wherein the 279 arginine polymorphism indicates susceptibility to COPD.

The invention is in a class of invention which the CAFC has characterized as “the unpredictable arts such as chemistry and biology.” *Mycogen Plant Sci., Inc. v. Monsanto Co.*, 243 F.3d 1316, 1330 (Fed. Cir. 2001).

The unpredictability of the art and the state of the prior art

The art teaches the exon 6, codon 279 arginine mutation is found at rs2664538. The art indicates this nucleic acid mutation exists at G2660A.

Lose et al. (Thorax, Vol. 60, pages 623-628, 2005) teaches the MMP-9 Arg279Gln mutation was not associated with asthma or asthma severity (abstract, page 626, col. 1). As seen in Table 3, the Arg279Gln polymorphism frequencies are provided.

Ganter et al. (International J. of Immunogenetics, Vol. 32, pages 233-236, 2005) teaches an association study of polymorphisms with MMP-9 and bronchial asthma. Ganter teaches the R279Q polymorphism within the MMP-9 gene were not associated with asthma. Ganter further teaches that in haplotype analysis, no association was found with asthma.

Nakashima et al. (Biochemical and Biophysical Research Communications, Vol. 344, pages 300-307, 2006) teaches analysis of polymorphisms within MMP-9 with asthma. Nakashima investigates whether variants of MMP-9 were related to childhood atopic asthma in Japanese populations by resequencing the MMP-9 gene, carrying out linkage disequilibrium mapping and conducting an association study with regard to the LD pattern (page 301, col. 1). Nakashima teaches 4841 was in complete LD with 2660G>A (the instantly claimed polymorphism)(page 303, col. 1). Nakashima teaches that SNP 10, namely 4841 which is in complete LD with 2660, is not associated with childhood atopic asthma (page 304, Table 3).

Saitoh et al. (International J. of Molecular medicine, Vol. 17, pages 621, 626, 2006) teaches analysis of MMP variants in Japanese and Egyptian subjected. Saitoh illustrates different ethnic groups may have varying associations. For example, in Table III, it is seen the Japanese population demonstrated an association with 6727, whereas Egyptian populations failed to demonstrate an association. Thus, different populations appear to show varying associations with COPD.

The art teaches genetic variations and associations are often irreproducible. Hirschhorn et al. (Genetics in Medicine. Vol. 4, No. 2, pages 45-61, March 2002) teaches that most reported associations are not robust. Of the 166 associations studied three or more times, only 6 have been consistently replicated. Hirschhorn *et al.* suggest a number of reasons for the irreproducibility of studies, suggesting population stratification, linkage disequilibrium, gene-gene or gene-environment interactions, and weak genetic effects and lack of power are possible factors that lead to such irreproducibility. Hirschhorn *et al.* caution that the current irreproducibility of most association studies should raise a cautionary alarm when considering their use as diagnostics and prognostics (p. 60, Col. 2). Thus, Hirschhorn cautions in drawing

conclusions from a single report of an association between a genetic variant and disease susceptibility.

Additionally, Ioannidis (Nature Genetics, Vol. 29, pages 306-309, November 2001) teaches that the results of the first study correlate only modestly with subsequent research on the same association (abstract). Ioannidis teaches that both bias and genuine population diversity might explain why early association studies tend to overestimate the disease protection or predisposition conferred by a genetic polymorphism (abstract).

The art teaches p-values are used to assess whether studies are “real” or “pure chance”. Thisted (May 1998) discuss what a p-value is. Thisted states that the p-value is important to determining whether differences observed are “real”. Thisted states that “it has become scientific convention to say that p-values exceeding 0.05 (one in twenty) just aren't strong enough to be the sole evidence that two treatments being studied really differ in their affects” (page 5). Therefore, it is clear that significance in the form of a p-value helps to determine whether the analysis was due to chance alone or demonstrates a difference between two groups.

Guidance in the Specification.

The specification provides no evidence that the broad scope of the claims may be used as broadly as claimed.

The specification teaches, COPD is a general term that includes several overlapping lung conditions that share the common functional problem of airflow limitation. Chronic *bronchitis*, one of these lung conditions, is defined clinically as chronic productive cough. *Emphysema*, which is defined pathologically, is determined functionally by the decrease in elastic recoil and the increased resistance in the airways.

Asthma with fixed airflow obstruction is included in the American Thoracic Society (ATS) definition of COPD and may be characterized as obstruction with a large reversible component although there is no clear recommendation of the degree of reversibility (page 2, lines 3-10).

The specification teaches a higher prevalence of the 279Arg homozygote genotype and the heterozygote genotype was seen in participants with COPD compared to non-COPD patients. The specification teaches the trend was not significant in Hispanic participants (page 30, lines 6-7). The specification further teaches that no statistical differences in distribution for any of the genotypes were observed between COPD and non-COPD participants in the Women's Cohort (page 30, lines 8-10).

Table 3 illustrates that the heterozygosity in non-Hispanic white individuals is not associated with COPD, however, the rare homozygosity shows a statistical significance with COPD. Table 3 illustrates that no significant association was found in Hispanics from the Veterans' cohort or any individuals from the Lovelace cohort. Table 4 illustrates that the Woman's cohort has no significant association with COPD. Table 4 also illustrates that Hispanic individuals failed to show an association with COPD.

The guidance provided by the specification amounts to an invitation for the skilled artisan to try and follow the disclosed instructions to make and use the claimed invention.

Quantity of Experimentation

The quantity of experimentation in this area is extremely large since there is a significant number of parameters which would have to be studied to enable the skilled artisan to practice the claimed invention as broadly as claimed.

The claims are broadly drawn to any Hispanic and non-Hispanic white men. The specification and the art illustrate that different ethnic groups have different patterns of association. The specification illustrates that the MMP-9 279 polymorphism is **not** statistically associated with COPD in Hispanic individuals. The art further teaches differences in association patterns in Japanese and Egyptian individuals. It is unpredictable whether a particular ethnicity is associated with a COPD excluding asthma and chronic bronchitis without further unpredictable experimentation. It is trial and error experimentation to determine whether the mutation is associated with COPD in any particular ethnicity.

The claims are broadly drawn to an association between a COPD and the presence of the 279 arginine polymorphism. The specification and the art teach a COPD encompasses bronchitis, emphysema, asthma, for example. Here, the specification teaches that heterozygous Gln279Arg was **not** associated with non-Hispanic white COPD whereas an association with rare homozygosity in non-Hispanic white was seen. While the skilled artisan could continue to perform additional experimentation to analyze the association of the 279 arginine polymorphism and any association with COPD, it is unpredictable whether any amount of experimentation would be able to replicate the instant analysis and association with a COPD. This would require significant inventive effort, with each of the many intervening steps, upon effective reduction to practice, not providing any guarantee of success in the succeeding steps.

Level of Skill in the Art

The level of skill in the art is deemed to be high.

Conclusion

In the instant case, as discussed above, in a highly unpredictable art where the art teaches the difficulties associated with association studies and phenotypes, it is unpredictable whether the skilled artisan could practice the broad scope of the instant claims. Further, the art and the specification provide insufficient guidance to overcome the art recognized problems. Thus given the broad claims in an art whose nature is identified as unpredictable, the unpredictability of that art, the large quantity of research required to define these unpredictable variables, the lack of guidance provided in the specification, the absence of a working example and the negative teachings in the prior art balanced only against the high skill level in the art, it is the position of the examiner that it would require undue experimentation for one of skill in the art to perform the method of the claim as broadly written.

Response to Arguments

The response traverses the rejection. The response asserts that the claims have been amended to require Hispanic and non-Hispanic white men and a COPD excluding asthma and chronic bronchitis. The specification, page 2, lines 3-9, appear to include chronic bronchitis, emphysema and asthma as lung conditions within the general term COPD. The claims have been limited to COPD which is not asthma, or chronic bronchitis, thus, the claims appear to be limited to emphysema based upon the definition of COPD provided in the specification.

The response further asserts that the claims have been amended to require Hispanic and non-Hispanic white men. The response states that the specification teaches that there is a higher prevalence of the 279 Arg homozygote genotype and the

Art Unit: 1634

heterozygote genotype in participants with COPD compared to non-COPD participants. And the trend is predicated to be seen in a Hispanic population when the pool of Hispanic participants with COPD increases to the size seen for non-Hispanic white participants exhibiting the trend. This argument has been considered but is not convincing because the data provided in the specification does not support such conclusions. First, the claims are limited to COPD excluding asthma and chronic bronchitis but no analysis of a population of Hispanic and non-Hispanic white men with emphysema has been studied. Second, the specification, Table 3, illustrates that the herterozygosity in non-Hispanic white individuals is not associated with COPD, however, the rare homozygosity show a statistical significance with COPD. Table 3 illustrates that no significant association was found in Hispanics from the Veterans' cohort or any individuals from the Lovelace cohort. Table 4 also illustrates that Hispanic individuals failed to show an association with COPD. Therefore, the polymorphism 279 does not indicate susceptibility to emphysema in Hispanic and non-Hispanic white men as evidenced by the data in the specification.

The response states that Saitoh is directed to MMP14 which is different than MMP9 and thus the response states there is no relevance. This argument has been reviewed but is deemed not persuasive. It is clear that different ethnic populations have different associations with different SNPs. Here, the instant 279 polymorphism is no exception, as further evidenced by the data in the specification.

The response states that there is no undue experimentation since the procedure can be easily reproduced. This argument has been reviewed but is deemed not

Art Unit: 1634

persuasive. Given the data and statistical analysis provided in the specification, there is no data that suggests that an association between the presence of the 279 polymorphism and emphysema in Hispanic and non-Hispanic white men can be reproduced.

Thus for the reasons above and those already of record, the rejection is maintained.

Conclusion

8. No claims allowable.

9. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Jeanine Goldberg whose telephone number is

Art Unit: 1634

(571) 272-0743. The examiner can normally be reached Monday-Friday from 7:00 a.m. to 4:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached on (571) 272-0735.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

The Central Fax Number for official correspondence is (571) 273-8300.

**/Jeanine A Goldberg/
Primary Examiner, Art Unit 1634
December 2, 2008**